v3.26.1
Commitments and Contingencies (Details)
$ in Thousands
12 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Long-Term Purchase Commitment [Line Items]      
Accumulated accrual contractual costs $ 42,500    
Research and development expense 681,812 $ 550,413 $ 439,909
Batoclimab      
Long-Term Purchase Commitment [Line Items]      
Research and development expense 39,000    
HanAll Biopharma Co., Ltd. (Immunovant)      
Long-Term Purchase Commitment [Line Items]      
Potential material future milestone payments 420,000    
Bayer AG (Pulmovant, Inc.)      
Long-Term Purchase Commitment [Line Items]      
Potential material future milestone payments $ 280,000    
LNP Technology (Genevant)      
Long-Term Purchase Commitment [Line Items]      
Royalty-related receipts percentage 0.20